National Cancer Institute; Notice of Meeting, 56365-56366 [07-4862]
Download as PDF
rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 72, No. 191 / Wednesday, October 3, 2007 / Notices
changes made to the PIN. Where
comments do not result in a revision to
the PIN, explanations will be provided.
Background: HRSA has received
numerous requests for clarification
regarding the program guidelines,
requirements, and application process
for the FQHC Look-Alike program. The
purpose of the FQHC Look-Alike PIN is
to respond to these requests for
clarification and to make the application
process more consistent with section
330 grant programs.
The Omnibus Budget Reconciliation
Acts of 1989, 1990, and 1993 amended
section 1905 of the Social Security Act
to create a new category of facility under
Medicaid and Medicare known as
Federally Qualified Health Centers
(FQHCs). The Social Security Act
§ 1905(l)(2)(B) definition of an FQHC
included an entity which, based on the
recommendation of HRSA, is
determined to meet the requirements of
the section 330 grant program but does
not receive the grant. This category of
health centers has been labeled FQHC
Look-Alikes.
To ensure that there are appropriate
numbers of health centers to serve the
millions of uninsured and underinsured
populations throughout the country,
FQHC Look-Alike status was made
available to those entities that do not
receive funding under section 330 but
operate and provide services similar to
grant-funded programs. As such, FQHC
Look-Alikes are expected to
demonstrate a commitment to serve all
populations residing in their respective
medically underserved communities
regardless of their ability to pay and to
satisfy all of the administrative,
management, governance and servicerelated requirements that apply to
section 330 funded health centers.
Benefits of obtaining FQHC Look-Alike
status include eligibility for enhanced
Medicaid and Medicare reimbursement,
participation in the 340(b) Federal Drug
Pricing Program, and automatic Health
Professional Shortage Area designation.
HRSA is responsible for managing the
FQHC Look-Alike program and
submitting recommendations to the
Centers for Medicare and Medicaid
Services (CMS) for designation as
FQHCs; however, CMS has the final
authority to designate applicants as
FQHCs. The organizations are
recertified annually to assure they are in
compliance with these regulations.
For
questions regarding this notice, please
contact Cicely Nelson at (301) 594–
4496.
FOR FURTHER INFORMATION CONTACT:
VerDate Aug<31>2005
18:31 Oct 02, 2007
Jkt 211001
Dated: September 24, 2007.
Elizabeth M. Duke,
Administrator.
[FR Doc. E7–19507 Filed 10–2–07; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Director’s Council of Public
Representatives.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Director’s Council of
Public Representatives.
Date: October 26, 2007.
Time: 8:30 a.m. to adjournment.
Agenda: Key topics for this meeting will
focus on public engagement in the
biomedical and behavioral research process.
Further information will be available on the
COPR Web site in mid-October at
www.copr.nih.gov.
Place: National Institutes of Health,
Building 31, Conference Room 6, 9000
Rockville Pike, Bethesda, MD 20892.
Contact Person: Kelli L. Carrington,
Executive Secretary/Public Liaison Officer,
Office of Communications and Public
Liaison, Office of the Director, National
Institutes of Health, 9000 Rockville Pike,
Building 1, Room 344, Bethesda, MD 20892,
301–594–4575, carringk@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
www.copr.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
56365
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: September 26, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4864 Filed 10–2–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Cancer Institute Clinical Trials
Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Cancer
Institute Clinical Trials Advisory Committee.
Date: November 14, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: Update on the progress of the
implementation of the Clinical Trials
Working Group.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Room 10,
Bethesda, MD 20892.
Contact Person: Sheila A. Prindiville, MD,
Director, Coordinating Center for Clinical
Trials, Office of the Director, National Cancer
Institute, National Institutes of Health, 6120
Executive Blvd., Suite 507, Bethesda, MD
20892, 301–451–5048,
prindivs@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
E:\FR\FM\03OCN1.SGM
03OCN1
56366
Federal Register / Vol. 72, No. 191 / Wednesday, October 3, 2007 / Notices
Cancer Control, National Institutes of Health,
HHS)
Dated: September 26, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4862 Filed 10–2–07; 8:45 am]
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Child Health and
Human Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
rwilkins on PROD1PC63 with NOTICES
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; The Role of Human
Milk-Morrow—SEP.
Date: October 19, 2007.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ramada Inn Rockville, 1775
Rockville Pike, Rockville, MD 20852.
Contact Person: Rita Anand, PhD,
Scientific Review Administrator, Division of
Scientific Review, National Institute of Child
Health and Human Development, NIH, 6100
Executive Blvd., Room 5B01, Bethesda, MD
20892, (301) 496–1487,
anandr@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: September 25, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4863 Filed 10–2–07; 8:45 am]
BILLING CODE 4140–01–M
VerDate Aug<31>2005
18:31 Oct 02, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; MATHIAS–
P01.
Date: October 25–26, 2007.
Time: 6 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Ramesh Vemuri, PhD,
Scientific Review Office, National Institute
on Aging, National Institutes of Health, 7201
Wisconsin Avenue, Suite 2C–212, Bethesda,
MD 20892, 301–402–7700, rv23r@nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Sex
Differences in Health and Longevity.
Date: October 31–November 1, 2007.
Time: 5 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites, Washington, DC
20015.
Contact Person: Wilbur C. Hadden, PhD,
Health Science Administrator, National
Institute on Aging, Gateway Building, Room
2C–212, 7201 Wisconsin Avenue, Bethesda,
MD 20892, haddenw@mail.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Bousfield
Review Meeting.
Date: November 6, 2007.
Time: 12 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway, 7802 Wisconsin Avenue, 2C–212,
Bethesda, MD 20895, (Telephone Conference
Call).
Contact Person: Ramesh Vemuri, PhD,
Scientific Review Office, National Institute
on Aging, National Institutes of Health, 7201
Wisconsin Avenue, Suite 2C–212, Bethesda,
MD 20892, 301–402–7700, rv23r@nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Health,
Aging, and the Life-Course.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Date: November 7, 2007.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Bethesda, MD 20770, (Telephone Conference
Call).
Contact Person: Wilbur C. Hadden, PhD,
Health Science Administrator, National
Institute on Aging, Gateway Building, Room
2C–212, 7201 Wisconsin Avenue, Bethesda,
MD 20892, haddenw@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: September 26, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4865 Filed 10–2–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Disease; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Allergy, Immunology,
and Transplantation Research Committee,
Allergy, Immunology and Transplantation
Research Committee (AITRC).
Date: October 25, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Bethesda North Hotel and
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Katrin Eichelberg, PhD.,
Scientific Review Administrator, Scientific
Review Program, Division of Extramural
Activities, NIAID/NIH/DHHS, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892, (301) 496–0808,
keichelberg@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
E:\FR\FM\03OCN1.SGM
03OCN1
Agencies
[Federal Register Volume 72, Number 191 (Wednesday, October 3, 2007)]
[Notices]
[Pages 56365-56366]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-4862]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the National Cancer Institute Clinical Trials Advisory Committee.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: National Cancer Institute Clinical Trials
Advisory Committee.
Date: November 14, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: Update on the progress of the implementation of the
Clinical Trials Working Group.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Room 10, Bethesda, MD 20892.
Contact Person: Sheila A. Prindiville, MD, Director,
Coordinating Center for Clinical Trials, Office of the Director,
National Cancer Institute, National Institutes of Health, 6120
Executive Blvd., Suite 507, Bethesda, MD 20892, 301-451-5048,
prindivs@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399,
[[Page 56366]]
Cancer Control, National Institutes of Health, HHS)
Dated: September 26, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-4862 Filed 10-2-07; 8:45 am]
BILLING CODE 4140-01-M